Skip to main content

Table 1 Characteristics of patients in the study population

From: Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review

CharacteristicEU5a
N = 813
France
N = 146
Germany
N = 175
Italy
N = 173
Spain
N = 141
UK
N = 173
Median age at diagnosis, years (IQR)66 (58–74)65 (57–73)68 (60–74)65 (57–72)66 (61–74)65 (57–75)
Male, n (%)477 (59)83 (57)106 (61)99 (57)85 (60)103 (60)
SCT during total at-risk period, n (%)b317 (39)64 (44)58 (33)73 (42)49 (35)65 (38)
ISS stage at diagnosis, n (%)
 1120 (15)22 (15)23 (13)28 (16)27 (19)22 (13)
 2282 (35)46 (32)49 (28)56 (32)58 (41)75 (43)
 3380 (47)74 (51)95 (54)78 (45)51 (36)71 (41)
 Unknown31 (4)3 (2)8 (5)11 (6)5 (4)5 (3)
ECOG performance status at 1 L initiation, n (%)
 0138 (17)11 (8)34 (19)43 (25)19 (14)36 (21)
 1467 (57)86 (59)110 (63)84 (49)77 (55)103 (60)
 2181 (22)44 (30)27 (15)43 (25)37 (26)26 (15)
 ≥ 320 (3)5 (3)3 (2)3 (2)7 (5)2 (1)
 Unknown8 (1)01 (1)01 (1)6 (4)
Circumstances that led to MM diagnosis, n (%)
 Bone pain513 (63)97 (66)109 (62)96 (56)95 (67)111 (64)
 HC174 (21)30 (21)29 (17)30 (17)30 (21)52 (30)
 VF188 (23)37 (25)45 (26)42 (24)22 (16)35 (20)
 OF34 (4)4 (3)6 (3)13 (8)6 (4)6 (4)
 SCC29 (4)5 (3)4 (2)8 (5)4 (3)7 (4)
 ≥ 1 bone-related problemc634 (78)117 (80)135 (77)128 (74)110 (78)137 (79)
 ≥ 1 HC, VF, OF or SCC359 (44)67 (46)71 (41)79 (46)56 (40)79 (46)
 ≥ 1 VF, OF or SCC233 (29)45 (31)52 (30)58 (34)30 (21)42 (24)
 Renal impairment187 (23)29 (20)55 (31)25 (15)26 (18)49 (28)
Presentation at the initiation of 1 L, n (%)
 ≥ 2 bone lesions598 (74)111 (76)138 (79)127 (73)96 (68)118 (68)
  1. 1 L first-line treatment, ECOG Eastern Cooperative Oncology Group, EU5 five European countries (France, Germany, Italy, Spain and the UK), HC hypercalcemia, IQR interquartile range, ISS international staging system, MM multiple myeloma, OF other non-vertebral fracture, SCC spinal cord compression, SCT stem cell transplantation, UK United Kingdom, VF vertebral fracture
  2. aAggregated EU5 data have been weighted based on the MM incidence in each country so base sizes for individual countries may not equal the EU5 total
  3. bOverall study period from MM diagnosis to disease progression following 1 L
  4. cAny of bone pain, HC, VF, OF and SCC